CMNDClearmind Medicine Inc.vs its industry peers
A metric-by-metric comparison of Clearmind Medicine Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CMNDEsta | $950037#4 | — | — | — | — | 26.6%#5 | — | — | — | — | -99.8%#4 | — |
| CELG.RI | — | — | — | — | -0.2%#2 | 178.8%#1 | 21.8%#1 | 30.1%#1 | 14.0%#1 | 7#1 | — | — |
| CLCS | — | — | — | — | — | 15.2%#6 | — | — | — | — | — | — |
| CMMB | $639M#2 | 61.7x#1 | 51.8x#3 | — | — | 35.5%#4 | — | -72.9%#2 | — | — | -63.7%#3 | — |
| CMPS | $1.6B#1 | — | 19.0x#2 | — | — | -73.9%#8 | — | -319.1%#4 | — | — | 83.4%#1 | — |
| CNBX | — | — | — | — | -100.0%#4 | 54.8%#2 | — | — | — | — | — | — |
| CNTB | $50M#3 | — | 1.9x#1 | 781.4x#1 | -99.8%#3 | -255.0%#9 | -90740.6%#3 | -206.5%#3 | — | — | -48.9%#2 | — |
| CPMD | — | — | — | — | 66.1%#1 | -12.4%#7 | -245.8%#2 | — | — | — | — | — |
| CTRVP | — | — | — | — | — | 37.3%#3 | — | -647.5%#5 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-01.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice